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Abstract
Objectives: To assess the potential of an online platform, PatientsLikeMe.com (PLM), for research in multiple sclerosis (MS).
An investigation of the role of body mass index (BMI) on MS disease course was conducted to illustrate the utility of the
platform.
Methods: First, we compared the demographic characteristics of subjects from PLM and from a regional MS center. Second,
we validated PLM’s patient-reported outcome measure (MS Rating Scale, MSRS) against standard physician-rated tools.
Finally, we analyzed the relation of BMI to the MSRS measure.
Results: Compared with 4,039 MS Center patients, the 10,255 PLM members were younger, more educated, and less often
male and white. Disease course was more often relapsing remitting, with younger symptom onset and shorter disease
duration. Differences were significant because of large sample sizes but small in absolute terms. MSRS scores for 121 MS
Center patients revealed acceptable agreement between patient-derived and physician-derived composite scores
(weighted kappa=0.46). The Walking domain showed the highest weighted kappa (0.73) and correlation (rs=0.86)
between patient and physician scores. Additionally, there were good correlations between the patient-reported MSRS
composite and walking scores and physician-derived measures: Expanded Disability Status Scale (composite rs=0.61,
walking rs=0.74), Timed 25 Foot Walk (composite rs=0.70, walking rs=0.69), and Ambulation Index (composite rs=0.81,
walking rs=0.84). Finally, using PLM data, we found a modest correlation between BMI and cross-sectional MSRS (rho=0.17)
and no association between BMI and disease course.
Conclusions: The PLM population is comparable to a clinic population, and its patient-reported MSRS is correlated with
existing clinical instruments. Thus, this online platform may provide a venue for MS investigations with unique strengths
(frequent data collection, large sample sizes). To illustrate its applicability, we assessed the role of BMI in MS disease course
but did not find a clinically meaningful role for BMI in this setting.
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Introduction
Investigations of factors associated with progressive disease in
multiple sclerosis (MS) have been hampered by the variable and
slow course of the disease, a lack of robust biomarkers and the
costs of generating large datasets longitudinally. The emergence of
online patient-centered research platforms holds great promise for
certain forms of clinical research by providing rapid access to data
from large numbers of patients at frequent intervals. However, the
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e59707quality and validity of data collected online must be assessed
critically.
PatientsLikeMe (www.patientslikeme.com; PLM) is an online
platform that includes 29,570 subscribers reporting having MS (as
of October 2012). In addition to personal and disease character-
istics, individuals also report their disease severity using an MS
Rating Scale (MSRS) designed by PLM [1]. Currently, while
several validated patient-reported outcome measures of MS
disease severity exist, some with online platform experience as in
the case of the North American Research Committee on Multiple
Sclerosis (NARCOMS) [2–4], there is no ‘‘gold standard’’ for data
capture through online platforms. The MSRS has previously
undergone psychometric validation and shown high internal
consistency, concordant validity with the NARCOMS Patient-
Derived Disease Step, and demonstrated adequate known-groups
validity. The instrument has been made available for free by
PatientsLikeMe under Creative Commons license [1].
To determine the potential and limitations of this platform for
future investigations, our study aimed first to determine whether
PLM members reporting MS were comparable to patients with
MS followed at a large regional MS referral center. Then, the
MSRS was validated in a clinical setting. Finally, the potential of
this platform was tested by assessing the role of body mass index
(BMI), a risk factor for MS [5–7], on disease course, a phase of the
disease for which limited data exist in this context [8].
Methods
I. Comparison of Demographic and Disease
Characteristics of PLM Members with Patients from the
Partners Multiple Sclerosis Center
Subjects. PLM is an online research platform based in
Cambridge, Massachusetts, designed to allow patients to share
data about their conditions, treatments, symptoms and comorbid-
ities through structured data collection [9], but with some features
of an online social network. Members join the site with the explicit
understanding that any data provided will be shared anonymously
but openly, including with pharmaceutical manufacturers, from
which the company derives its funding. Use of the system has been
associated with positive measures of patient literacy, communica-
tion and support [10], with development of other patient-reported
outcomes [11–13], and with clinical insights [14]. From the over
29,570 members of PLM reporting a diagnosis of MS, members
aged 18 and above were selected if (1) they provided at least 4 of
the 5 following baseline characteristics: age, sex, disease type, age
at first symptom, age at diagnosis; and (2) they had updated their
profiles at least twice between 1/1/2009 and 8/31/2011
(n=10,255). Both demographic (age, race, ethnicity, gender,
family history of MS, education) and disease characteristics
(disease type, age at first symptoms, use of disease modifying
therapy (DMT)) were obtained from the PLM databases.
The Partners MS Center (Brigham and Women’s Hospital) is a
regional MS referral center in the Northeastern United States.
Detailed electronic records of patient visits to the Center are
captured using structured encounter forms and stored within an
Oracle software-based relational database designed to follow the
longitudinal histories of patients with demyelinating diseases. Data
derived from this cohort have been extensively described [15]. We
included all subjects aged 18 or older, with an MS diagnosis by
2005 McDonald Criteria, who were evaluated clinically at least
twice at the Partners MS Center since 1/1/2009 (n=4,039). IRB
approval was obtained for the analysis of the existing PLM and
Partners data from the Partners Healthcare Human Research
Committee, our Institutional Review Board. Given the consent
documents governing the use of the Partners MS center data, we
could not determine whether any MS Center patients were also
members of PLM.
Statistical analysis. T-tests were used for continuous out-
comes and chi-squared analyses were used for categorical
outcomes. Identical analyses were performed for subsets of patients
treated with glatiramer acetate and interferons. Due to missing
data for certain individuals, percentages for each variable were
calculated based on a different sample sizes.
II. Validation of the Patient-reported MSRS
Subjects. Patient- and physician-derived MSRS scores were
compared for a sample of MS patients seen at the Partners MS
Center over 20 days in November 2011. All patients aged 18 or
older, who carried a diagnosis of MS based on 2005 McDonald
Criteria by an MS Center physician, were fluent in English, and
who presented for routine neurological follow up at the Partners
MS Center were approached. IRB approval was obtained from
the Partners Healthcare Human Research Committee. Verbal
informed consent was obtained from participants, in compliance
with the IRB, because it was determined that the research
presented no more than minimal risk of harm to subjects and
involved no procedures for which written consent is normally
required outside the research context. A study fact sheet describing
the study was provided with the questionnaire to each patient
approached, in compliance with the IRB. Thus only consenting
individuals would complete the questionnaire, and blank ques-
tionnaires would be stored for those who did not consent. None of
the 162 patients who were approached refused participation. Of
these patients, 34 were unable to participate due to the constraints
of the MS Center schedule for clinical encounters. In addition, 7
patients who filled out the questionnaire did not have a definite
MS diagnosis. This resulted in 121 subjects and their physician
completing an MSRS evaluation.
MSRS score. In this 7-item questionnaire, patients rate their
disability on a 0–4 scale in 7 areas (walking, use of upper
extremities, speech disturbance, vision, dysphagia, cognitive or
affective disturbance, and sensory disturbance). Total scores range
from 0–28 (Table S1).
Clinical assessment. Patients completed the MSRS inde-
pendently of the physician prior to the clinical encounter.
Following the clinical encounter, each patient’s physician then
completed the MSRS form, which covers functions routinely
assessed and logged in the Oracle database, and then provided
scores for the Expanded Disability Status Scale (EDSS) [16],
Ambulation Index (AI [17]) and Timed 25 foot walk (T25FW
[18]).
Statistical analysis. For comparisons of patient- and physi-
cian-derived MSRS scores, a weighted kappa statistic was
calculated for each MSRS domain, as well as for the composite
(sum) score to assess the agreement between the two raters. For the
composite score, a Bland-Altman plot for the patient and
physician score was also created. In addition, Spearman’s
correlation coefficient was also calculated to assess the level of
association between the two raters. Finally, the proportion of
agreement between physician and patient was calculated for each
MSRS domain, and reason for lack of concordance (physician
rates score higher, vs. patient rates score higher) was recorded.
Nonparametric Spearman correlation coefficients were also
calculated between EDSS, T25FW, and AI and both patient-
and physician-derived MSRS composite and walking domain
subscores. This allowed us to assess the criterion validity (the
extent to which the measure of interest corresponds with an
An Online Platform for Multiple Sclerosis Research
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subscore.
III. Investigation of BMI on MS Disease Course in PLM
Subjects. PLM members were selected in an identical
manner to (I), but with profiles updated at least twice between
1/1/2009 and 1/1/2012 (n=10,433). IRB approval was obtained
for analysis of these existing PLM data from the Partners
Healthcare Human Research Committee.
Body mass index. Self-reported height, weight, and calcu-
lated BMI (kg/m2) were included for all PLM subjects in the
study. The following measurements were excluded: height ,55 or
.85 inches, weight ,70 or .540 lbs, and BMI .190.
Statistical analysis. BMI was first classified according to
WHO criteria to examine the distribution of this parameter in our
sample: underweight (,18.50 kg/m
2), normal weight (18.50–
24.99 kg/m
2), overweight (25.00–29.99 kg/m
2), and obese
($30.00 kg/m
2). Then, a cross-sectional analysis was performed
correlating continuous BMI at most recent data entry point with
MSRS composite score, using nonparametric correlations and
adjusting for age, sex, race, disease duration, and disease type.
Third, to assess the impact of BMI on longitudinal accumulation
of disability (MSRS), we used two mixed models with random
slopes and intercepts and robust standard errors to estimate the
interaction between BMI and follow-up time, controlling for age,
sex, race, disease duration, and disease type, and the interaction
between disease type and follow-up time. In the first model, the
predictor of interest was the earliest BMI available for each subject
after symptom onset. In the second model, the predictor of interest
was BMI within the first three months of symptom onset, which
was available for a subset of subjects.
Only de-identified PLM data were transferred to the Brigham
and Women’s Hospital research team for quality control and
analysis. All statistical analyses were performed using either the R
version 2.14.2 (www.r-project.org) or SAS Software (Version 9.3).
Results
I. Comparison of Subject and Disease Characteristics
between PLM Members and Partners MS Center Subjects
In comparing how an online patient population recruited at a
national level (PLM members) relates to a patient population
found at a large regional MS center (the Boston-based Partners
MS Center patient population), we found small (in absolute terms)
but statistically significant differences for all tested variables
(p,0.0001 for all comparisons, Table 1). Specifically, PLM
members were younger, more educated, more often female, and
less often white. Further, the reported disease course of PLM
members was more often relapsing remitting, with younger age at
symptom onset and shorter disease duration. A family history of
MS was also less common among PLM members. Similar
proportions of PLM and MS Center subjects used glatiramer
acetate (24% vs. 25%), but more PLM subjects used interferon
beta (29% vs. 18%). For both treatment groups, the differences in
demographic characteristics between the MS Center and PLM
populations were similar to those reported between the MS Center
and the complete PLM population examined (Table S2).
II. Validation of Patient Reported MSRS
To assess the validity of the patient reported MSRS instrument
deployed in PLM’s online platform, we administered this
instrument to 121 MS patients at the Partners MS Center, with
comparable demographic and disease characteristics to the entire
MS Center population described in Table 1 (Table S3), and
with the spectrum of disability seen at our Center (median EDSS:
2, range: 0–8.5).
Good agreement between the patient- and physician-derived
composite MSRS scores was observed (weighted kappa=0.43,
Table 2; Figure S1). The two scores were strongly correlated
(Spearman rank-order correlation coefficient, rs=0.693). When
we examined individual domains, the walking score had the
highest level of agreement (weighted kappa=0.732) and the
highest level of correlation (rs=0.856). There was also good
agreement and association for upper extremity weakness and
swallowing (weighted kappa .0.4, rs.0.5). The other four
domains had lower levels of agreement between physician and
patient assessments but all were significantly correlated
(p,0.0001). The relationships between the patient and physician
scores for each domain are shown in Table 2 and Table S4a–g.
There did not appear to be any systematic under- or over-
reporting of symptoms by either patients or physicians, as
evidenced by the percentages of patients vs. physicians providing
a higher score (Table 2).
When we compared physician-derived MSRS scores with
disease severity measures routinely captured at the Partners MS
Center, there was good correlation between the composite MSRS
and EDSS (rs=0.838, N=117,), Timed 25 foot walk (T25FW)
(rs=0.703, N=98), and ambulation index (AI) (rs=0.813,
N=107). In terms of subdomains, the MSRS walking domain
Table 1. Comparison of PLM members’ individual and
disease characteristics with those of patients followed at the
Partners MS Center.
Variable PLM MS Center Comparison
N=10255 N=4039 p-value
Mean (SD) Mean (SD)
Current Age, yrs 44.8 (10.6) 47.8 (12.0) ,0.0001
Age at first symptom, yrs 32.8 (10.0) 34.2 (10.8) ,0.0001
Disease Duration, yrs 12.0 (9.3) 13.7 (10.5) ,0.0001
%%
Gender (% F) 80.1 74.8 ,0.0001
Family History of MS (% yes) 22.4 25.5 0.0002
Race ,0.0001
White 90.4 92.4
African American 5.1 4.6
Other 4.5 3.0
MS course ,0.0001
Relapsing-remitting 77.6 70.2
Secondary progressive 12.0 22.6
Primary progressive 7.3 6.2
Progressive relapsing 3.1 1.0
Education Level ,0.0001
Less than 12 years 2.2 2.5
Completed High School 14.7 16.9
Some College 42.2 54.8
Completed College 25.8 12.2
Post Graduate 15.1 13.6
NB. For individual variables, as some subjects had missing data, the N used for
calculation of percentages was lower than the total N of respondents.
doi:10.1371/journal.pone.0059707.t001
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T25FW (rs=0.693), and AI (rs=0.840) (p,0.001 for all). We also
compared patient-derived MSRS composite scores with physician-
derived clinical scales; while the correlations were weaker, these
remained highly significant (p,0.001): EDSS (rs=0.609), T25FW
(rs=0.497), and AI (rs=0.591). Correlations with the MSRS
walking domain score were somewhat stronger: EDSS (rs=0.738),
T25FW (rs=0.650), and AI (rs=0.738).
III. Investigation of BMI and Disease Course
Having established the clinical relevance of the MSRS, we
analyzed prospectively collected data from PLM members to
assess the role of BMI in disease severity, as assessed by self-
reported MSRS. At last data entry, the mean BMI among PLM
members was 27.6 kg/m
2 (n=10,433), with 25.7% subjects who
were overweight (BMI.24.9) and 26.7% subjects who were obese
(BMI.29.9) (Table 3).
Cross-sectionally, we noted a very modest correlation
(rho=0.17, n=1336) between greater BMI (continuous variable)
and greater MSRS (Table 4). While significant because of the
large sample size (p,0.001), the magnitude of this correlation is
sufficiently small that it is unlikely to be of clinical relevance. Using
a mixed model approach, we also assessed whether, in patients
who have MS, BMI at a given time affects the subsequent
trajectory of disease severity as assessed by repeated MSRS
measures. In this analysis of prospectively collected MSRS, we did
not see an effect of BMI on MSRS trajectory (estimate (95%
CI)=0.0133 (20.00013, 0.0267), p=0.05, n=1695), after
adjusting for disease duration, age, sex, race, disease type, and
the interaction between disease type and follow-up time. When
available (n=236), we also assessed the relation of reported BMI
at symptom onset with subsequent MSRS trajectory, and we also
found no effect of BMI at symptom onset with subsequent disease
course (estimate (95% CI)=0.0137 (20.0162, 0.0436), p=0.37,
n=236). Overall, these longitudinal analyses – along with the
cross-sectional analysis - suggest that BMI does not have a strong
effect on MS disease severity as estimated by the self-reported
MSRS instrument.
Discussion
In this study, we report good correlation of the patient-reported
MSRS measure developed by PLM with standard clinical
assessment measures used in MS, such as the EDSS. The
availability of this online instrument and of the large PLM
membership provides a useful, complementary platform for MS
clinical research. It does not replace rigorous, prospective cohort
studies or targeted clinical research projects performed in
academic MS centers; instead, it offers a different option, that
has an opportunity to leverage the frequent sampling of data from
a large subject population.
While we found small demographic differences between PLM
members with recent profile updates and patients at our MS
center, they were modest in absolute terms. It should be noted that
both sets of subjects represent somewhat biased subsets of the
overall MS patient population; this limitation is somewhat
mitigated by their large sample size but needs to be clearly stated.
Interestingly, the differences that we describe between the patient
populations we compared – including that PLM members had a
younger age, higher education, larger proportion of women and
lower proportion of self-reported white non-Hispanic origin - are
slightly at odds with other demographic surveys of users of online
tools, that have noted greater use and more frequent use by
individuals who are white, female, older, with higher incomes,
with good internet skills, and who are not employed [20]. We
limited our comparative analysis to the subset of PLM members
with recent profile updates, in order to examine active members
who are likely to participate in ongoing online investigations;
however, it is possible that these individuals differ in demographic
terms from the general PLM population. The greater proportion
Table 2. Comparison of patient- and physician- scored MSRS.
AGREEMENT BETWEEN PATIENT AND PHYSICIAN
(% Scores) Weighted kappa statistic Correlation
Domain
Patient rated
higher
Perfect
Agreement
Patient rated
lower (95% CI) Spearman r p-value
Walking 20.0 62.5 17.5 0.730 (0.652, 0.807) 0.856 ,0.0001
Arms 22.5 61.7 15.8 0.479 (0.341, 0.617) 0.552 ,0.0001
Vision 23.3 56.7 20.0 0.342 (0.198, 0.486) 0.426 ,0.0001
Speech 10.0 79.2 10.8 0.307 (0.115, 0.500) 0.367 ,0.0001
Swallowing 8.3 85.0 6.7 0.419 (0.210, 0.627) 0.506 ,0.0001
Cognitive 27.1 45.8 27.1 0.338 (0.205, 0.471) 0.446 ,0.0001
Sensory 37.0 41.2 21.8 0.320 (0.196, 0.443) 0.414 ,0.0001
Composite Score 47.5 16.9 35.6 0.462 (0.363, 0.554) 0.693 ,0.0001
doi:10.1371/journal.pone.0059707.t002
Table 3. Distribution of self-reported BMI in the PLM
population.
BMI Distribution
Within 3 months
of first symptom Last data entry
N 1173 10433
Underweight 42 (3.6%) 330 (3.2%)
Normal 476 (40.6%) 4058 (38.9%)
Overweight 313 (26.7%) 2970 (28.5%)
Obese 342 (29.2%) 3075 (29.5%)
Mean (SD) 27.36 (6.78) 27.56 (6.78)
Median 25.84 26.2
doi:10.1371/journal.pone.0059707.t003
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fact that they had more relapsing onset disease. We also compared
the PLM population to the 31,232 respondents from NARCOMS,
a large and well-described registry-based cohort [21,22] (Table
S5). Here, we found statistically significant but small absolute
differences in demographic characteristics, further suggesting that
the PLM members, offer a reasonable alternative platform for MS
clinical research that could yield insights that are generalizable to
other MS populations after appropriate control for confounders.
In this study, we explored the use of PLM to answer a timely
clinical question in which the current literature offers conflicting
results: the relationship between excess body weight and MS
disease course in the North American population that is becoming
increasingly heavier. Obesity in an individual’s mother [23] or
during adolescence of the individual [5,6] may increase the risk for
MS and perhaps for a relapsing onset [7]. However, in adulthood,
insofar as it is possible to disentangle the effects of age, disability
and comorbidities, individuals with MS may have lower body mass
index (BMI) than age-matched controls [8,24–27]. Only one prior
study, by the North American Research Committee on Multiple
Sclerosis (NARCOMS), examined longitudinal data and suggested
that fluctuations in BMI are not associated with changes in disease
severity as measured by Patient-determined disease steps [8].
Here, using a large sample size and prospectively collected data,
we report consistent results suggesting that there is no evidence for
increased BMI having a strong effect on disability in MS: we noted
a very modest correlation between BMI and MSRS in the cross-
sectional analysis (rho=0.17, n=1336) and only a nominally
significant association in the analysis of the longitudinal MSRS
data (estimate (95% CI)=0.0133 (20.00013, 0.0267)), suggesting
that there is no clinically meaningful role for BMI in disability for
MS in most individuals. Individuals do tend to under-estimate
their BMI in self-reports [28]; however, because we examined
BMI as a continuous variable this under-estimation should not
influence the statistical estimate of this relationship on longitudinal
course. However, we cannot exclude the possibility that BMI may
have a very weak effect on the accumulation of disability, that it
may influence other measures of disability in MS or that it may
have a role in a subset of individuals. Further, the adverse health
consequences of high BMI are well documented and doubtlessly
impact the life course of MS patients [7], irrespective of a direct
effect of BMI on MS disability.
Our findings and those of others relating BMI and disease
severity in adults [8], contrast with the increased risk of MS
associated with higher BMI during adolescence noted in prior
studies [5,6], possibly through immunologic modulation by
hormones such as leptin and adiponectin [29–32]. This disjunction
of a risk factor’s role in susceptibility and disease course has been
suggested for other susceptibility factors such as EBV infection
[33] and genetic risk factors [34], but not for cigarette smoking
[35,36] and vitamin D levels [37], which may influence both
disease susceptibility and disease course. Additionally, because
high BMI is associated with low vitamin D status, the association
between BMI and risk of MS may in fact be confounded by
vitamin D status [38]. As we better understand the functional
consequences of these various risk factors, we may begin to see
how they influence downstream molecular events leading to MS
onset and/or disability.
There are challenges and limitations to online research
platforms, including biases arising from the digital divide, issues
of privacy, autonomy and data storage, variable and inconsistent
data sampling schedules, and lack of objective validation of
reported data such as height and weight [39,40]. Also, in the
absence of a gold standard for patient reported outcomes, it is not
feasible to determine whether the physician or patient is ‘‘right’’,
only to understand the broader areas of agreement and
discordance. For example, a patient may be more aware of
sensory disturbances, but a clinician may better appreciate the
broader range of gait disturbance seen in clinical practice. In this
study a bias towards greater MSRS agreement between provider
and patient may have existed, as the provider relied on the patient
during the clinical interview to answer some questions, such as
those pertaining to swallowing. Also, as with any clinical
instrument, test-retest reliability is critical to enable powerful
analysis; while we did not assess this feature of the MSRS as part of
our study, the reliability of the MSRS has been previously
evaluated and revealed one-week test-retest correlations of r=0.91
(p,0.001) [1]. While not as comprehensive as a clinical
examination or as biomedically grounded as an MRI scan, a
patient reported outcome of disability such as the MSRS has the
advantage of being rapid and free to administer; it also has the
potential to enable patients themselves to learn more about the
progression of their illness through self-monitoring. Further,
missing data and incomplete participation by many members
are important limitations that require rigorous quality control
measures such as the ones that we implemented. In this study,
from an initial 28,025 members reporting at least some
information pertaining to MS, limiting the analysis to subjects
with at least two separate dates of data entry in the study period
and implementing the other quality measures reduced the analysis
to a final N of 10,255 subjects. Finally, because online platforms
are relatively new, the follow up time may not yet be sufficient long
to detect clinically meaningful changes in the MSRS.
In conclusion, online research remains in its infancy and
continues to pose ethical and methodological challenges. None-
theless, the opportunity of capturing an assessment of disability on
Table 4. Cross-sectional and longitudinal associations of BMI with disease severity, as measured by the MSRS.
statistic p-value
Cross-sectional association
Adjusted Spearman correlation between BMI at last data entry and MSRS (N=6229)* Adjusted r=0.14 ,0.001
Longitudinal association
Interaction term between BMI within 3 months of symptom onset and follow-up time
(N=236)**
Estimate=0.0137 95% CI=20.0162, 0.0436 0.37
Interaction term between BMI at first data entry and follow-up time (N=1695)** Estimate=0.0133 95% CI=20.00013, 0.0267 0.05
*All models adjusted for current age, sex, disease duration (years), disease course, and race.
**Models also adjusted for interaction between disease type and follow-up time.
doi:10.1371/journal.pone.0059707.t004
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possible using more episodic data collection strategies such as those
collected by NARCOMS. Prospective tracking of symptoms in
‘‘real time’’ may eventually allow researchers to assess whether
certain symptoms such as increases in fatigue or fluctuations in
‘‘brain fog’’ can serve as harbingers for clinical attacks or be useful
in assessing a patient’s clinical trajectory or response to disease-
modifying therapy. The PLM member population therefore offers
an intriguing new platform for MS investigations. Its results, after
appropriate consideration of potential demographic and other
confounders, may be generalizable to and replicable in the larger
patient population seen in large MS centers.
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